Eli Lilly and Company reported positive topline results from the TOGETHER-PsO Phase 3b clinical trial. The study evaluated Zepbound (tirzepatide) combined with Taltz (ixekizumab) against Taltz monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.
The combination therapy met its primary and all key secondary endpoints at 36 weeks. It demonstrated superior skin clearance and weight loss compared to Taltz alone.
In the combination group, 27.1% of patients achieved complete skin clearance (PASI 100) and at least 10% weight loss. Only 5.8% of patients treated with Taltz monotherapy reached the same benchmarks.
Results suggest that treating obesity with Zepbound significantly reduces the clinical burden of psoriasis. Eli Lilly shares rose 0.25% in pre-market trading following the announcement. The company intends to discuss these findings with regulators and submit the data for publication.